December 10-13, 2022; New Orleans, Louisiana
Intensified consolidation with daratumumab, bortezomib, lenalidomide, and dexamethasone showed clinical benefit in patients with ultra-high‒risk newly diagnosed multiple myeloma and primary plasma cell leukemia in the phase II OPTIMUM/MUKnine trial.